JP2022526842A5 - - Google Patents

Info

Publication number
JP2022526842A5
JP2022526842A5 JP2021559986A JP2021559986A JP2022526842A5 JP 2022526842 A5 JP2022526842 A5 JP 2022526842A5 JP 2021559986 A JP2021559986 A JP 2021559986A JP 2021559986 A JP2021559986 A JP 2021559986A JP 2022526842 A5 JP2022526842 A5 JP 2022526842A5
Authority
JP
Japan
Prior art keywords
biotin
insulin
glycero
approximately
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526842A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027762 external-priority patent/WO2020210697A1/en
Publication of JP2022526842A publication Critical patent/JP2022526842A/ja
Publication of JP2022526842A5 publication Critical patent/JP2022526842A5/ja
Pending legal-status Critical Current

Links

JP2021559986A 2019-04-12 2020-04-10 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 Pending JP2022526842A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833228P 2019-04-12 2019-04-12
US62/833,228 2019-04-12
US202062988748P 2020-03-12 2020-03-12
US62/988,748 2020-03-12
PCT/US2020/027762 WO2020210697A1 (en) 2019-04-12 2020-04-10 Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Publications (2)

Publication Number Publication Date
JP2022526842A JP2022526842A (ja) 2022-05-26
JP2022526842A5 true JP2022526842A5 (https=) 2023-04-17

Family

ID=72748579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559986A Pending JP2022526842A (ja) 2019-04-12 2020-04-10 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法

Country Status (7)

Country Link
US (3) US10918700B2 (https=)
EP (1) EP3952904A4 (https=)
JP (1) JP2022526842A (https=)
AU (1) AU2020271901A1 (https=)
CA (1) CA3136665A1 (https=)
WO (1) WO2020210697A1 (https=)
ZA (1) ZA202108217B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP7306718B2 (ja) * 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863896A (en) * 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
EP1087753A4 (en) * 1998-05-19 2004-06-30 Sdg Inc TARGETED LIPOSOMAL DRUG ADMINISTRATION SYSTEM
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
DE50209996D1 (de) * 2001-11-16 2007-05-31 Medinnovation Ag Medizinische pumpvorrichtung
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1858545A2 (en) 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US20100129428A1 (en) * 2005-05-23 2010-05-27 Sdg, Inc. Supra molecular construct for delivery of interferon to a mammal
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
TWI614024B (zh) * 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US20120035105A1 (en) * 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
JP7306718B2 (ja) 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
EP3483629B1 (en) * 2017-11-09 2021-12-29 Veoneer Sweden AB Detecting a parking row with a vehicle radar system
KR20200106912A (ko) 2018-01-05 2020-09-15 에스디지,인코포레이티드 당뇨병을 치료하기 위한 지질 기반 나노입자를 포함하는 조성물

Similar Documents

Publication Publication Date Title
JP2023120371A5 (https=)
JP2025085727A5 (https=)
US20220160841A1 (en) Glucose-responsive insulin delivery microneedle system
JP7656353B2 (ja) 向上した安定性を有する脂質ベースのナノ粒子
JP2020510705A5 (https=)
JP2021509900A5 (https=)
CN110339166B (zh) 一种利拉鲁肽多囊脂质体及其制备方法和应用
CN105688191A (zh) 促胰岛素释放肽的混悬制剂及其应用
JP2022526842A5 (https=)
JP7517691B2 (ja) 糖尿病を処置するための脂質ベースのナノ粒子を含む組成物
US12161749B2 (en) Microneedle-array patches with glucose-responsive matrix for closed-loop insulin delivery
US20240139288A1 (en) Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
US11077173B2 (en) Lipid-based nanoparticles and methods using same
Chen Controlled release of insulin from a novel biodegradable injectable gel system
HK40015408A (en) Lipid-based nanoparticles with enhanced stability
HK1245105B (en) Glucose-responsive insulin delivery system using hypoxia-sensitive nanocomposites